Alzheon Pipeline2018-10-01T13:53:42+00:00

Our Pipeline

Our lead oral product, ALZ-801, is ready for Phase 3 in Alzheimer’s

Focused on mild Alzheimer’s patients
Targeted patient selection based on APOE4 genotype
Granted Fast Track Designation by FDA for development in Alzheimer’s disease

ALZ-801 is an improved prodrug formulation of tramiprosate which showed

Promising clinical signals in a subset of Alzheimer’s patients
Well tolerated, long-term safety evaluated in 2,000 patients at effective clinical dose

Our lead pre-clinical candidate is ALZ-1903

New chemical entity
More potent inhibitor of amyloid misfolding

Discovery Platform

Rich and diverse compound libraries enabled by the novel mechanism of action
Designed to inhibit the misfolding of amyloids and other proteins associated with neurodegenerative diseases

Consistent Efficacy Across Biomarker & Clinical Studies

Alzheon Pipeline - Efficacy Across Biomarker & Clinical Studies

Urgent Need with ~5.7 Million Alzheimer’s Patients in U.S.1

~35 Million Worldwide Patients & $1 Trillion Cost1

Alzheon Alzheimers unmet need